Is N-Acetyl Semax just a longer-lasting Semax?

Not exactly, and the distinction matters. Acetylating the N-terminus does measurably improve resistance to proteolysis, which is well documented. But the same modification also changes how the peptide binds copper and zinc, and no published human study has shown that the acetylated form produces stronger or longer-lasting central effects. It is best understood as a related molecule with better stability, not as a strictly superior version of Semax.

How does this differ from N-Acetyl Semax Amidate?

The amidate form adds a second modification: a C-terminal amide group on top of the N-terminal acetylation. Acetylation blocks aminopeptidases at one end; amidation blocks carboxypeptidases at the other. Capping both termini is intended to give greater stability still, but it is a distinct compound and carries even less dedicated research.

What research actually exists on the acetylated form specifically?

Very little, and it is chemistry rather than clinical work: a 2013 proteolytic-stability study and a 2016 metal-coordination study. The cognitive, neuroprotective and stroke findings people cite are from the unmodified parent peptide, so any expectation carried across to this analog is an inference, not a demonstrated result.

← All peptides

Cognitive & Nootropic

Research Chemical

N-Acetyl Semax

Also known as: N-Acetyl Semax, NA-Semax, Acetyl Semax, Semax Acetyl

An N-terminally acetylated form of Semax, modified to resist enzymatic breakdown. The acetylation itself is documented, but nearly all of the neurotrophic and clinical research that motivates interest in this compound was performed on unmodified Semax.

Mechanism of Action

N-Acetyl Semax shares the Semax core: a heptapeptide built from the ACTH(4-7) fragment with a C-terminal Pro-Gly-Pro extension (Met-Glu-His-Phe-Pro-Gly-Pro), derived from the ACTH(4-10) region but stripped of corticotropic activity. In the parent peptide, the documented effects are neurotrophic rather than hormonal: upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the hippocampus and cortex, modulation of dopaminergic and serotonergic signaling, interaction with melanocortin receptors, and inhibition of enkephalin-degrading enzymes. The modification in this analog is pharmacokinetic in intent: acetylating the N-terminus caps the free alpha-amino group that aminopeptidases require in order to begin cleaving the chain, and improved proteolytic stability for acetylated Semax has been measured directly across several biological media (Shevchenko et al., 2013). Two caveats belong with that. First, greater stability is not the same as greater or longer central activity, which has not been established for this analog in published human work. Second, acetylation is not pharmacologically inert: removing the free N-terminal amine measurably changes how the peptide coordinates copper(II) and zinc(II), with associated changes in biological behavior (Magri et al., 2016), so the acetylated molecule should not be assumed to be simply a longer-lasting Semax.

Half-life: Not characterized in humans for the acetylated form. The parent Semax is cleared from plasma within minutes while central effects persist for hours; N-terminal acetylation is intended to slow that degradation and has been shown to do so in vitro.
Administration Routes: intranasal, subcutaneous
Research Status: Research Chemical

N-Acetyl Semax

Also known as: N-Acetyl Semax, NA-Semax, Acetyl Semax, Semax Acetyl